Mitonuclear genotype remodels the metabolic and microenvironmental landscape of Hürthle cell carcinoma.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
24 06 2022
Historique:
entrez: 22 6 2022
pubmed: 23 6 2022
medline: 25 6 2022
Statut: ppublish

Résumé

Hürthle cell carcinomas (HCCs) display two exceptional genotypes: near-homoplasmic mutation of mitochondrial DNA (mtDNA) and genome-wide loss of heterozygosity (gLOH). To understand the phenotypic consequences of these genetic alterations, we analyzed genomic, metabolomic, and immunophenotypic data of HCC and other thyroid cancers. Both mtDNA mutations and profound depletion of citrate pools are common in HCC and other thyroid malignancies, suggesting that thyroid cancers are broadly equipped to survive tricarboxylic acid cycle impairment, whereas metabolites in the reduced form of NADH-dependent lysine degradation pathway were elevated exclusively in HCC. The presence of gLOH was not associated with metabolic phenotypes but rather with reduced immune infiltration, indicating that gLOH confers a selective advantage partially through immunosuppression. Unsupervised multimodal clustering revealed four clusters of HCC with distinct clinical, metabolomic, and microenvironmental phenotypes but overlapping genotypes. These findings chart the metabolic and microenvironmental landscape of HCC and shed light on the interaction between genotype, metabolism, and the microenvironment in cancer.

Identifiants

pubmed: 35731870
doi: 10.1126/sciadv.abn9699
pmc: PMC9216518
doi:

Substances chimiques

DNA, Mitochondrial 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eabn9699

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA232097
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA251543
Pays : United States

Références

Nat Commun. 2018 Aug 30;9(1):3533
pubmed: 30166553
Cancer Cell. 2016 Jan 11;29(1):104-116
pubmed: 26766592
Nat Biotechnol. 2016 Feb;34(2):155-63
pubmed: 26619011
J Nucl Med. 2003 Sep;44(9):1402-6
pubmed: 12960183
Mol Genet Metab. 2020 Sep - Oct;131(1-2):14-22
pubmed: 32768327
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Cell Metab. 2019 Apr 2;29(4):856-870.e7
pubmed: 30686744
Nat Metab. 2021 Apr;3(4):558-570
pubmed: 33833465
Cell Syst. 2018 Mar 28;6(3):301-313.e3
pubmed: 29396322
Nature. 2019 Jan;565(7740):495-499
pubmed: 30626970
Anal Chem. 2006 Jul 1;78(13):4281-90
pubmed: 16808434
J Nucl Med. 2006 Aug;47(8):1260-6
pubmed: 16883003
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Cell. 2014 Aug 14;158(4):929-944
pubmed: 25109877
J Clin Oncol. 2001 May 15;19(10):2616-25
pubmed: 11352953
Nat Commun. 2020 Jan 3;11(1):102
pubmed: 31900386
Science. 2017 Jan 20;355(6322):
pubmed: 28104840
Sci Signal. 2021 Jan 05;14(664):
pubmed: 33402335
Cancer Cell. 2014 Sep 8;26(3):319-330
pubmed: 25155756
Nat Rev Mol Cell Biol. 2021 Apr;22(4):266-282
pubmed: 33495651
J Chromatogr. 1977 Nov 11;142:497-503
pubmed: 914931
Nature. 2009 Nov 5;462(7269):108-12
pubmed: 19847166
Brain. 2005 Apr;128(Pt 4):711-22
pubmed: 15689364
Cancer Cell. 2018 Aug 13;34(2):242-255.e5
pubmed: 30107175
Cancer Cell. 2018 Aug 13;34(2):256-270.e5
pubmed: 30107176
Am J Surg Pathol. 2000 Sep;24(9):1247-56
pubmed: 10976699
J Clin Endocrinol Metab. 2013 May;98(5):E962-72
pubmed: 23543667
J Pathol. 1992 Jul;167(3):273-7
pubmed: 1381433
Nat Commun. 2013;4:2612
pubmed: 24113773
Genome Biol. 2016 Nov 17;17(1):231
pubmed: 27855702
Immunity. 2016 Aug 16;45(2):374-88
pubmed: 27496732
Thyroid. 2002 Feb;12(2):155-61
pubmed: 11916285
J Biol Chem. 2011 May 20;286(20):17777-84
pubmed: 21454630

Auteurs

Ian Ganly (I)

Human Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Eric Minwei Liu (EM)

Computational Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Fengshen Kuo (F)

Human Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Vladimir Makarov (V)

Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

Yiyu Dong (Y)

Human Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Jinsung Park (J)

Human Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Yongxing Gong (Y)

Human Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Alexander N Gorelick (AN)

Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Jeffrey A Knauf (JA)

Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

Elisa Benedetti (E)

Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.

Jacqueline Tait-Mulder (J)

CRUK Beatson Institute, Glasgow, UK.

Luc G T Morris (LGT)

Human Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

James A Fagin (JA)

Human Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Andrew M Intlekofer (AM)

Human Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Jan Krumsiek (J)

Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.

Payam A Gammage (PA)

CRUK Beatson Institute, Glasgow, UK.
Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

Ronald Ghossein (R)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Bin Xu (B)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Timothy A Chan (TA)

Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

Ed Reznik (E)

Computational Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH